​
​

Jasper Therapeutics Ownership 2024 | Who Owns Jasper Therapeutics Now?

OverviewForecastRevenueFinancialsChart

Institutional Ownership

68.35%

Insider Ownership

4.95%

Retail Ownership

26.70%

Institutional Holders

39.00

Jasper Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
COWEN AND COMPANY, LLC----200,000-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----3,180,059-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----609-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----154,909-100.00%-Mar 31, 2024
STATE STREET CORP----229,994-100.00%-Mar 31, 2024
VANGUARD GROUP INC----4,092,958-100.00%-Mar 31, 2024
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----36,899-100.00%-Mar 31, 2024
MORGAN STANLEY----1,699,550-100.00%-Mar 31, 2024
BANK OF MONTREAL /CAN/----348,300-100.00%-Mar 31, 2024
GROUP ONE TRADING, L.P.----1-100.00%-Mar 31, 2024
KINGDON CAPITAL MANAGEMENT, L.L.C.----3,540,000-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----514,324-100.00%-Mar 31, 2024
GRIES FINANCIAL LLC----23,845-100.00%-Mar 31, 2024
TWO SIGMA INVESTMENTS, LP----54,168-100.00%-Mar 31, 2024
LAZARD ASSET MANAGEMENT LLC----11,500-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----904,477-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC----129,883-100.00%-Mar 31, 2024
BLACKROCK INC.----1,323,972-100.00%-Mar 31, 2024
MARINER, LLC----590,510-100.00%-Mar 31, 2024
BANK OF NEW YORK MELLON CORP----43,593-100.00%-Mar 31, 2024

Jasper Therapeutics's largest institutional shareholder is COWEN AND COMPANY, LLC, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
COWEN AND COMPANY, LLC----200,000-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----3,180,059-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----609-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----154,909-100.00%-Mar 31, 2024
STATE STREET CORP----229,994-100.00%-Mar 31, 2024
VANGUARD GROUP INC----4,092,958-100.00%-Mar 31, 2024
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----36,899-100.00%-Mar 31, 2024
MORGAN STANLEY----1,699,550-100.00%-Mar 31, 2024
BANK OF MONTREAL /CAN/----348,300-100.00%-Mar 31, 2024
GROUP ONE TRADING, L.P.----1-100.00%-Mar 31, 2024
KINGDON CAPITAL MANAGEMENT, L.L.C.----3,540,000-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----514,324-100.00%-Mar 31, 2024
GRIES FINANCIAL LLC----23,845-100.00%-Mar 31, 2024
TWO SIGMA INVESTMENTS, LP----54,168-100.00%-Mar 31, 2024
LAZARD ASSET MANAGEMENT LLC----11,500-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----904,477-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC----129,883-100.00%-Mar 31, 2024
BLACKROCK INC.----1,323,972-100.00%-Mar 31, 2024
MARINER, LLC----590,510-100.00%-Mar 31, 2024
BANK OF NEW YORK MELLON CORP----43,593-100.00%-Mar 31, 2024

The largest Jasper Therapeutics shareholder by % of total assets is COWEN AND COMPANY, LLC. The company owns 0.00 shares of Jasper Therapeutics (JSPR), representing 0.00% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
GROUP ONE TRADING, L.P.----1-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----609-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----11,144-100.00%-Mar 31, 2024
JANE STREET GROUP, LLC----11,209-100.00%-Mar 31, 2024
LAZARD ASSET MANAGEMENT LLC----11,500-100.00%-Mar 31, 2024
GRIES FINANCIAL LLC----23,845-100.00%-Mar 31, 2024
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----36,899-100.00%-Mar 31, 2024
BANK OF NEW YORK MELLON CORP----43,593-100.00%-Mar 31, 2024
TWO SIGMA INVESTMENTS, LP----54,168-100.00%-Mar 31, 2024
IEQ CAPITAL, LLC----54,500-100.00%-Mar 31, 2024
SUMMIT TRAIL ADVISORS, LLC----65,000-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC----129,883-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----154,909-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----191,155-100.00%-Mar 31, 2024
COWEN AND COMPANY, LLC----200,000-100.00%-Mar 31, 2024
STATE STREET CORP----229,994-100.00%-Mar 31, 2024
MONACO ASSET MANAGEMENT SAM----249,563-100.00%-Mar 31, 2024
BANK OF MONTREAL /CAN/----348,300-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----514,324-100.00%-Mar 31, 2024
MARINER, LLC----590,510-100.00%-Mar 31, 2024

As of Mar 31 2024, Jasper Therapeutics's largest institutional buyer is GROUP ONE TRADING, L.P.. The company purchased -1.00 stocks of JSPR, valued at -.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
VELAN CAPITAL INVESTMENT MANAGEMENT LP----11,219,036-100.00%-Mar 31, 2024
SOLEUS CAPITAL MANAGEMENT, L.P.----9,870,980-100.00%-Mar 31, 2024
CARLYLE GROUP INC.----8,761,891-100.00%-Mar 31, 2024
QIMING U.S. VENTURES MANAGEMENT, LLC----8,519,648-100.00%-Mar 31, 2024
OCTAGON CAPITAL ADVISORS LP----4,468,114-100.00%-Mar 31, 2024
VANGUARD GROUP INC----4,092,958-100.00%-Mar 31, 2024
OPALEYE MANAGEMENT INC.----3,985,340-100.00%-Mar 31, 2024
ALLY BRIDGE GROUP (NY) LLC----3,659,255-100.00%-Mar 31, 2024
KINGDON CAPITAL MANAGEMENT, L.L.C.----3,540,000-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----3,180,059-100.00%-Mar 31, 2024
NANTAHALA CAPITAL MANAGEMENT, LLC----2,228,265-100.00%-Mar 31, 2024
WOODLINE PARTNERS LP----1,732,993-100.00%-Mar 31, 2024
MORGAN STANLEY----1,699,550-100.00%-Mar 31, 2024
SATURN V CAPITAL MANAGEMENT LLC----1,386,215-100.00%-Mar 31, 2024
BLACKROCK INC.----1,323,972-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----904,477-100.00%-Mar 31, 2024
LANDSCAPE CAPITAL MANAGEMENT, L.L.C.----789,331-100.00%-Mar 31, 2024
SPHERA FUNDS MANAGEMENT LTD.----713,063-100.00%-Mar 31, 2024
MARINER, LLC----590,510-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----514,324-100.00%-Mar 31, 2024

As of Mar 31 2024, Jasper Therapeutics's biggest institutional seller is VELAN CAPITAL INVESTMENT MANAGEMENT LP. The company sold -11.22M shares of JSPR, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
VELAN CAPITAL INVESTMENT MANAGEMENT LP----11,219,036-100.00%-Mar 31, 2024
SOLEUS CAPITAL MANAGEMENT, L.P.----9,870,980-100.00%-Mar 31, 2024
CARLYLE GROUP INC.----8,761,891-100.00%-Mar 31, 2024
QIMING U.S. VENTURES MANAGEMENT, LLC----8,519,648-100.00%-Mar 31, 2024
OCTAGON CAPITAL ADVISORS LP----4,468,114-100.00%-Mar 31, 2024
VANGUARD GROUP INC----4,092,958-100.00%-Mar 31, 2024
OPALEYE MANAGEMENT INC.----3,985,340-100.00%-Mar 31, 2024
ALLY BRIDGE GROUP (NY) LLC----3,659,255-100.00%-Mar 31, 2024
KINGDON CAPITAL MANAGEMENT, L.L.C.----3,540,000-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----3,180,059-100.00%-Mar 31, 2024
NANTAHALA CAPITAL MANAGEMENT, LLC----2,228,265-100.00%-Mar 31, 2024
WOODLINE PARTNERS LP----1,732,993-100.00%-Mar 31, 2024
MORGAN STANLEY----1,699,550-100.00%-Mar 31, 2024
SATURN V CAPITAL MANAGEMENT LLC----1,386,215-100.00%-Mar 31, 2024
BLACKROCK INC.----1,323,972-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----904,477-100.00%-Mar 31, 2024
LANDSCAPE CAPITAL MANAGEMENT, L.L.C.----789,331-100.00%-Mar 31, 2024
SPHERA FUNDS MANAGEMENT LTD.----713,063-100.00%-Mar 31, 2024
MARINER, LLC----590,510-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----514,324-100.00%-Mar 31, 2024
BANK OF MONTREAL /CAN/----348,300-100.00%-Mar 31, 2024
MONACO ASSET MANAGEMENT SAM----249,563-100.00%-Mar 31, 2024
STATE STREET CORP----229,994-100.00%-Mar 31, 2024
COWEN AND COMPANY, LLC----200,000-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----191,155-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----154,909-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC----129,883-100.00%-Mar 31, 2024
SUMMIT TRAIL ADVISORS, LLC----65,000-100.00%-Mar 31, 2024
IEQ CAPITAL, LLC----54,500-100.00%-Mar 31, 2024
TWO SIGMA INVESTMENTS, LP----54,168-100.00%-Mar 31, 2024
BANK OF NEW YORK MELLON CORP----43,593-100.00%-Mar 31, 2024
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----36,899-100.00%-Mar 31, 2024
GRIES FINANCIAL LLC----23,845-100.00%-Mar 31, 2024
LAZARD ASSET MANAGEMENT LLC----11,500-100.00%-Mar 31, 2024
JANE STREET GROUP, LLC----11,209-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----11,144-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----609-100.00%-Mar 31, 2024
GROUP ONE TRADING, L.P.----1-100.00%-Mar 31, 2024

Jasper Therapeutics's largest sold out institutional shareholder by shares sold is VELAN CAPITAL INVESTMENT MANAGEMENT LP, sold -11.22M shares, valued at -, as of undefined.

Jasper Therapeutics Mutual Fund Holders

Name% Total AssetsTotal SharesChange AmountChange %Date
FRANKLIN STRATEGIC SERIES0.17%1,439,300--Jan 31, 2024
VANGUARD VALLEY FORGE FUNDS0.11%57,934--Mar 31, 2024
FRANKLIN STRATEGIC SERIES0.02%144,574144,574-Jan 31, 2024
VANGUARD INDEX FUNDS0.01%5,093,695--Mar 31, 2024
FIDELITY CONCORD STREET TRUST0.00%827,978--Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%74,930--Mar 31, 2024
SCHWAB CAPITAL TRUST0.00%36,899--Feb 29, 2024
ETF Series Solutions0.00%6,706--Jan 31, 2024
SCHWAB CAPITAL TRUST0.00%3,6893,689-Jan 31, 2024
USAA MUTUAL FUNDS TRUST0.00%8,645--Jan 31, 2024
iSHARES TRUST0.00%177,380--Mar 31, 2024
EQ ADVISORS TRUST0.00%11,532--Mar 31, 2024
AMERICAN CENTURY ETF TRUST0.00%100100-Feb 29, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%1,683--Mar 31, 2024

Jasper Therapeutics's largest mutual fund holder by % of total assets is "FRANKLIN STRATEGIC SERIES", owning 1.44M shares, compromising 0.17% of its total assets.

Jasper Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

DateHoldingsChange %
31 Dec, 2339-7.14%
30 Sep, 2342-14.29%
30 Jun, 2349-3.92%
31 Mar, 2351121.74%
31 Dec, 222321.05%
30 Sep, 2219-13.64%
30 Jun, 2222-8.33%
31 Mar, 2224-14.29%
31 Dec, 2128211.11%
30 Sep, 219-

As of 31 Dec 23, 39 institutions are holding Jasper Therapeutics's shares, representing a decrease of -7.14% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Dec, 2374,996,253-18.08%
30 Sep, 2391,546,6023.92%
30 Jun, 2388,090,697-5.98%
31 Mar, 2393,692,255362.76%
31 Dec, 2220,246,590-0.44%
30 Sep, 2220,335,4022.22%
30 Jun, 2219,894,189-0.80%
31 Mar, 2220,053,919-4.12%
31 Dec, 2120,914,592103.09%
30 Sep, 2110,298,176-

Jasper Therapeutics (JSPR) has 75.00M shares outstanding as of 31 Dec 23, down -18.08% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Dec, 2368.35%0.97%
30 Sep, 2383.82%0.84%
30 Jun, 2399.92%0.88%
31 Mar, 23106.28%20.15%
31 Dec, 2222.97%4.32%
30 Sep, 2223.07%4.53%
30 Jun, 2222.57%4.36%
31 Mar, 2222.75%4.04%
31 Dec, 2123.72%17.39%
30 Sep, 2111.68%-

As of 31 Dec 23, Jasper Therapeutics is held by 68.35% institutional shareholders, representing a 0.97% growth compared to 30 Sep 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Dec, 2317-
30 Sep, 2317-10.53%
30 Jun, 2319-57.78%
31 Mar, 2345350.00%
31 Dec, 221011.11%
30 Sep, 229-30.77%
30 Jun, 221362.50%
31 Mar, 228-63.64%
31 Dec, 2122144.44%
30 Sep, 219-

17 institutional shareholders have increased their position in JSPR stock as of 31 Dec 23 compared to 17 in the previous quarter (a 0.00% increase).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Dec, 23928.57%
30 Sep, 237-30.00%
30 Jun, 2310900.00%
31 Mar, 231-83.33%
31 Dec, 226200.00%
30 Sep, 222-33.33%
30 Jun, 223-62.50%
31 Mar, 228166.67%
31 Dec, 213-
30 Sep, 21--

9 institutional shareholders have reduced their position in JSPR stock as of 31 Dec 23 compared to 7 in the previous quarter (a 28.57% increase).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Dec, 2339-7.14%74,996,253-18.08%68.35%0.97%17-928.57%
30 Sep, 2342-14.29%91,546,6023.92%83.82%0.84%17-10.53%7-30.00%
30 Jun, 2349-3.92%88,090,697-5.98%99.92%0.88%19-57.78%10900.00%
31 Mar, 2351121.74%93,692,255362.76%106.28%20.15%45350.00%1-83.33%
31 Dec, 222321.05%20,246,590-0.44%22.97%4.32%1011.11%6200.00%
30 Sep, 2219-13.64%20,335,4022.22%23.07%4.53%9-30.77%2-33.33%
30 Jun, 2222-8.33%19,894,189-0.80%22.57%4.36%1362.50%3-62.50%
31 Mar, 2224-14.29%20,053,919-4.12%22.75%4.04%8-63.64%8166.67%
31 Dec, 2128211.11%20,914,592103.09%23.72%17.39%22144.44%3-
30 Sep, 219-10,298,176-11.68%-9---

Jasper Therapeutics Insider Shareholders Trades

Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jun 12, 2024Mahal Jeetinder Singhofficer Chief Operating OfficerS-SaleSell900$24.16$21.74K25,009
Mar 12, 2024Mahal Jeetinder Singhofficer Chief Operating OfficerS-SaleSell900$26.44$23.79K25,009

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jun 12, 2024Mahal Jeetinder Singhofficer Chief Operating OfficerS-SaleSell900$24.16$21.74K25,009
Mar 12, 2024Mahal Jeetinder Singhofficer Chief Operating OfficerS-SaleSell900$26.44$23.79K25,009

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jun 20, 2024Lucas Svetlanadirector-A-AwardBuy15,000$23.19$347.85K15,000
Jun 20, 2024Lucas Svetlanadirector Buy----
Jun 12, 2024Mahal Jeetinder Singhofficer Chief Operating OfficerM-ExemptBuy900$7.10$6.39K25,909
Jun 12, 2024Mahal Jeetinder Singhofficer Chief Operating OfficerS-SaleSell900$24.16$21.74K25,009
Jun 12, 2024Mahal Jeetinder Singhofficer Chief Operating OfficerM-ExemptBuy900$7.10$6.39K15,572
Jun 12, 2024MARTELL RONdirector, officer President, CEO and DirectorA-AwardBuy20,000--20,000
Jun 12, 2024MARTELL RONdirector, officer President, CEO and DirectorA-AwardBuy10,000$23.95$239.50K10,000
Jun 10, 2024Tucker Edwin Jonathanofficer Chief Medical OfficerA-AwardBuy400$4.17$1.67K400
Jun 10, 2024French Anna Louisedirector-A-AwardBuy7,500$25.41$190.57K7,500
Jun 10, 2024Nolet Chrisdirector-A-AwardBuy7,500$25.41$190.57K7,500
Jun 10, 2024Shizuru Judith Annedirector-A-AwardBuy7,500$25.41$190.57K7,500
Jun 10, 2024Kapoor Vishaldirector-A-AwardBuy7,500$25.41$190.57K7,500
Jun 10, 2024WIGGANS THOMAS Gdirector-A-AwardBuy7,500$25.41$190.57K7,500
Jun 10, 2024Brun Scott C.director-A-AwardBuy7,500$25.41$190.57K7,500
Jun 10, 2024EMSTER KURT VONdirector-A-AwardBuy7,500$25.41$190.57K7,500
Mar 12, 2024Mahal Jeetinder Singhofficer Chief Operating OfficerM-ExemptBuy900$7.10$6.39K25,909
Mar 12, 2024Mahal Jeetinder Singhofficer Chief Operating OfficerS-SaleSell900$26.44$23.79K25,009
Mar 12, 2024Mahal Jeetinder Singhofficer Chief Operating OfficerM-ExemptBuy900$7.10$6.39K16,472
Feb 20, 2024MARTELL RONdirector, officer President, CEO and DirectorA-AwardBuy100,000$17.95$1.79M100,000
Feb 20, 2024Mahal Jeetinder Singhofficer Chief Operating OfficerA-AwardBuy40,000$17.95$718.00K40,000

The last insider sell of Jasper Therapeutics's stock was made by Mahal Jeetinder Singh on Jun 12 2024, selling 900 shares at $24.16 per share (valued at $21.74K).

Jasper Therapeutics Insider Ownership Trends

All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 20241311300.00%
Q1 202481800.00%
Q4 202363200.00%
Q3 20231--
Q2 2023116183.33%
Q1 202362300.00%
Q4 20228--
Q3 2022---
Q2 20221250.00%
Q1 202218--
Q3 2021127171.43%
Q2 2021-3-
Q1 2021-7-
Q4 2020-8-
Q3 2020-9-
Q1 2020-4-
Q4 2019-1-

13 total buy trades, and 1 total sell trades (buy/sell ratio of 13.00%) were made by Jasper Therapeutics's insiders, as of Q2 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 2024-1-
Q1 202421200.00%
Q4 202351500.00%
Q3 2023---
Q2 2023-4-
Q1 202321200.00%
Q4 2022---
Q3 2022---
Q2 2022-2-
Q1 2022---
Q3 2021---
Q2 2021-3-
Q1 2021-6-
Q4 2020-8-
Q3 2020-9-
Q1 2020---
Q4 2019---

As of Q2 2024, Insider owners conducted 0 open market buy trades and 1 open market sell trades of Jasper Therapeutics's stocks.

Jasper Therapeutics Peer Ownership

TickerCompany
EQEquillium, Inc.
IKNAIkena Oncology, Inc.
EWTXEdgewise Therapeutics, Inc.
HOOKHOOKIPA Pharma Inc.
INBXInhibrx, Inc.
LIANLianBio
INZYInozyme Pharma, Inc.
ORICORIC Pharmaceuticals, Inc.
ELDNEledon Pharmaceuticals, Inc.
DSGNDesign Therapeutics, Inc.
ABOSAcumen Pharmaceuticals, Inc.
XLOXilio Therapeutics, Inc.
EPIXESSA Pharma Inc.
LYRALyra Therapeutics, Inc.
GRTXGalera Therapeutics, Inc.
ELYMEliem Therapeutics, Inc.

JSPR Ownership FAQ

Jasper Therapeutics is owned by institutional shareholders (68.35%), insiders (4.95%), and public (26.70%). The largest institutional shareholder of Jasper Therapeutics is COWEN AND COMPANY, LLC (0% of total shares) and the top mutual fund owner is FRANKLIN STRATEGIC SERIES (0.17% of total shares).

Jasper Therapeutics's major institutional shareholders are COWEN AND COMPANY, LLC, BANK OF AMERICA CORP /DE/, WELLS FARGO & COMPANY/MN, NORTHERN TRUST CORP, and STATE STREET CORP. The top five shareholders own together 0% of the company's share outstanding.

As of Dec 2023, there are 39 institutional shareholders of Jasper Therapeutics.

COWEN AND COMPANY, LLC owns 0 shares of Jasper Therapeutics, representing 0% of the company's total shares outstanding, valued at $0 (as of Mar 2024).

As of Mar 2024, BANK OF AMERICA CORP /DE/ holds 0 shares of Jasper Therapeutics (JSPR), compromising 0% of the company, valued at $0.

WELLS FARGO & COMPANY/MN is the third largest holder of Jasper Therapeutics. The company owns 0 of the company's shares outstanding (worth $0).